Praxis Precision Medicines (PRAX) - Cash Funds Calculated per Share

Praxis Precision Medicines focuses on rare genetic forms of epilepsy to achieve accelerated therapy approval. Cash per share for Praxis Precision Medicines demonstrates an upward trend, where 26.64 shows the level of this metric. Financial stability is based on the experienced management's ability to attract venture capital and the use of personal genetic data to minimize scientific risks when developing targeted drugs.
Analytical breakdowns for Praxis Precision Medicines

This multiple allows for the determination of an asset's intrinsic value by comparing liquid reserves with the number of shares to assess the business's financial autonomy. By analyzing the amount of free cash per share, an investor can see the real margin of safety for Praxis Precision Medicines (PRAX) to fund the costly development of precision drugs against resistant forms of epilepsy, which is critically important for biotech companies in the R&D stage.